Angiotensin II Type 1 Receptor Antagonist, TCV-1 16, Prevents Neointima Formation in Injured Arteries in the Dog

Access this Article

Author(s)

Abstract

We investigated the effect of an angiotensin (Ang) II antagonist, (+/-)-1-(cyclohexyloxy- carbonyloxy)-ethyl 2-ethoxy-1-[[2′-(<I>1H</I>-tetrazol-5-yl)biphenyl-4-yl]methyl]-1<I>H</I>-benzimidazole-7-carboxylate (TCV-116), on neointima formation in dog artery injured by a balloon catheter. Dogs were orally treated with 10 mg/kg TCV-116 or placebo twice a day for 5 weeks. After treatment with these drugs for 1 week, the right carotid artery was injured by a balloon catheter. The left carotid artery was regarded as the control. In the group treated with placebo, neointima formation in the injured arteries was observed. The activities of angiotensin converting enzyme (ACE) and chymase in the injured carotid arteries were increased 2.56- and 3.26-fold compared with those in the non-injured arteries, respectively. The neointimal area in dogs treated with placebo and TCV-116 were 0.51±0.07 and 0.21±0.07 mm<SUP>2</SUP>, respectively, and this difference was significant. In conclusion, an Ang II antagonist, TCV-116, prevented neointima formation by blocking the action of Ang II generated by both ACE and chymase in the injured arteries.

Journal

  • The Japanese Journal of Pharmacology

    The Japanese Journal of Pharmacology 79(4), 455-460, 1999-04-01

    The Japanese Pharmacological Society

References:  25

Cited by:  2

Codes

  • NII Article ID (NAID)
    10008683507
  • NII NACSIS-CAT ID (NCID)
    AA00691188
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    00215198
  • NDL Article ID
    4706100
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-D199
  • Data Source
    CJP  CJPref  NDL  J-STAGE 
Page Top